[In high risk patients cyclooxygenase inhibitor plus proton pump inhibitor].
Bolten
W W
WW
Klaus Miehlke Klinik, Leibnizstr. 23, D-65191 Wiesbaden.
D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D003327:Coronary Disease / Q000188:drug therapy; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008565:Membrane Proteins; D010438:Peptic Ulcer Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D011451:Prostaglandin-Endoperoxide Synthases; D017494:Proton Pumps / Q000187:drug effects*; D012307:Risk Factors; D013276:Stomach Ulcer / Q000139:chemically induced / Q000517:prevention & control*
D000897:Anti-Ulcer Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D005343:Fibrinolytic Agents; D007527:Isoenzymes; D008565:Membrane Proteins; D017494:Proton Pumps; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin